Matches in SemOpenAlex for { <https://semopenalex.org/work/W2167156722> ?p ?o ?g. }
- W2167156722 endingPage "5807" @default.
- W2167156722 startingPage "5800" @default.
- W2167156722 abstract "Purpose To determine the maximum-tolerated dose (MTD) and to assess the safety, pharmacokinetics, and evidence of antitumor activity of AMG 479, a fully human monoclonal antibody to insulin-like growth factor receptor 1 (IGF-1R). Patients and Methods Patients with advanced solid malignancies or non-Hodgkin's lymphoma received escalating doses of AMG 479 intravenously (IV) every 2 weeks (Q2W). Blood samples were assayed to determine pharmacokinetic parameters and IGF-1R occupancy on neutrophils; fluorodeoxyglucose–positron emission tomography scans were used to assess tumor metabolic effects. Results Fifty-three patients received 312 infusions of AMG 479 Q2W. Overall, the most common grades 1 to 2 toxicities were fatigue, thrombocytopenia, fever, rash, chills, and anorexia. One dose-limiting toxicity (ie, grade 3 thrombocytopenia) occurred in a patient at 20 mg/kg during course 1; grade 3 thrombocytopenia (n = 8) and grade 3 transaminitis elevations (n = 1) also were reported but not in the escalation phase. The maximum-planned dose of 20 mg/kg was safely administered; thus, an MTD was not reached. High levels of neutrophil IGF-1R binding and increases from baseline in serum IGF-1 levels were observed in the 12- and 20-mg/kg cohorts. Tumor responses included one durable complete response (CR) and one unconfirmed partial response (PR) in two patients with Ewing/primitive neuroectodermal tumors and included one PR and one minor response in two patients with neuroendocrine tumors. The patients with Ewing/PNET who had a CR have remained disease free on therapy after 28 months. Conclusion AMG 479 can be administered safely at 20 mg/kg IV Q2W. The absence of severe toxicities, attainment of serum concentrations associated with high levels of IGF-1R binding on neutrophils, and provocative antitumor activity warrant additional studies of this agent." @default.
- W2167156722 created "2016-06-24" @default.
- W2167156722 creator A5003380386 @default.
- W2167156722 creator A5022467575 @default.
- W2167156722 creator A5031165814 @default.
- W2167156722 creator A5036446086 @default.
- W2167156722 creator A5040850986 @default.
- W2167156722 creator A5047962331 @default.
- W2167156722 creator A5048060803 @default.
- W2167156722 creator A5049243227 @default.
- W2167156722 creator A5057503413 @default.
- W2167156722 creator A5059195446 @default.
- W2167156722 creator A5060992997 @default.
- W2167156722 creator A5063058991 @default.
- W2167156722 creator A5070570779 @default.
- W2167156722 creator A5076109830 @default.
- W2167156722 creator A5081614843 @default.
- W2167156722 date "2009-12-01" @default.
- W2167156722 modified "2023-10-18" @default.
- W2167156722 title "Phase I, Pharmacokinetic, and Pharmacodynamic Study of AMG 479, a Fully Human Monoclonal Antibody to Insulin-Like Growth Factor Receptor 1" @default.
- W2167156722 cites W1892156002 @default.
- W2167156722 cites W1924823925 @default.
- W2167156722 cites W1972083618 @default.
- W2167156722 cites W1999371114 @default.
- W2167156722 cites W2001778920 @default.
- W2167156722 cites W2034710772 @default.
- W2167156722 cites W2040104879 @default.
- W2167156722 cites W2042854276 @default.
- W2167156722 cites W2047636637 @default.
- W2167156722 cites W2054711858 @default.
- W2167156722 cites W2055624165 @default.
- W2167156722 cites W2061054148 @default.
- W2167156722 cites W2078515109 @default.
- W2167156722 cites W2107294830 @default.
- W2167156722 cites W2138128689 @default.
- W2167156722 cites W2151444534 @default.
- W2167156722 cites W2162996009 @default.
- W2167156722 cites W2169555656 @default.
- W2167156722 doi "https://doi.org/10.1200/jco.2009.23.6745" @default.
- W2167156722 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19786654" @default.
- W2167156722 hasPublicationYear "2009" @default.
- W2167156722 type Work @default.
- W2167156722 sameAs 2167156722 @default.
- W2167156722 citedByCount "274" @default.
- W2167156722 countsByYear W21671567222012 @default.
- W2167156722 countsByYear W21671567222013 @default.
- W2167156722 countsByYear W21671567222014 @default.
- W2167156722 countsByYear W21671567222015 @default.
- W2167156722 countsByYear W21671567222016 @default.
- W2167156722 countsByYear W21671567222017 @default.
- W2167156722 countsByYear W21671567222018 @default.
- W2167156722 countsByYear W21671567222019 @default.
- W2167156722 countsByYear W21671567222020 @default.
- W2167156722 countsByYear W21671567222021 @default.
- W2167156722 countsByYear W21671567222022 @default.
- W2167156722 countsByYear W21671567222023 @default.
- W2167156722 crossrefType "journal-article" @default.
- W2167156722 hasAuthorship W2167156722A5003380386 @default.
- W2167156722 hasAuthorship W2167156722A5022467575 @default.
- W2167156722 hasAuthorship W2167156722A5031165814 @default.
- W2167156722 hasAuthorship W2167156722A5036446086 @default.
- W2167156722 hasAuthorship W2167156722A5040850986 @default.
- W2167156722 hasAuthorship W2167156722A5047962331 @default.
- W2167156722 hasAuthorship W2167156722A5048060803 @default.
- W2167156722 hasAuthorship W2167156722A5049243227 @default.
- W2167156722 hasAuthorship W2167156722A5057503413 @default.
- W2167156722 hasAuthorship W2167156722A5059195446 @default.
- W2167156722 hasAuthorship W2167156722A5060992997 @default.
- W2167156722 hasAuthorship W2167156722A5063058991 @default.
- W2167156722 hasAuthorship W2167156722A5070570779 @default.
- W2167156722 hasAuthorship W2167156722A5076109830 @default.
- W2167156722 hasAuthorship W2167156722A5081614843 @default.
- W2167156722 hasConcept C111113717 @default.
- W2167156722 hasConcept C112705442 @default.
- W2167156722 hasConcept C126322002 @default.
- W2167156722 hasConcept C22979827 @default.
- W2167156722 hasConcept C2778570526 @default.
- W2167156722 hasConcept C2778594517 @default.
- W2167156722 hasConcept C2779338263 @default.
- W2167156722 hasConcept C29730261 @default.
- W2167156722 hasConcept C71924100 @default.
- W2167156722 hasConcept C90924648 @default.
- W2167156722 hasConcept C98274493 @default.
- W2167156722 hasConceptScore W2167156722C111113717 @default.
- W2167156722 hasConceptScore W2167156722C112705442 @default.
- W2167156722 hasConceptScore W2167156722C126322002 @default.
- W2167156722 hasConceptScore W2167156722C22979827 @default.
- W2167156722 hasConceptScore W2167156722C2778570526 @default.
- W2167156722 hasConceptScore W2167156722C2778594517 @default.
- W2167156722 hasConceptScore W2167156722C2779338263 @default.
- W2167156722 hasConceptScore W2167156722C29730261 @default.
- W2167156722 hasConceptScore W2167156722C71924100 @default.
- W2167156722 hasConceptScore W2167156722C90924648 @default.
- W2167156722 hasConceptScore W2167156722C98274493 @default.
- W2167156722 hasIssue "34" @default.
- W2167156722 hasLocation W21671567221 @default.
- W2167156722 hasLocation W21671567222 @default.
- W2167156722 hasOpenAccess W2167156722 @default.